Full-year 2025 revenue increased to $176.2 million, exceeding the high end of previous guidance. Life Sciences Services revenue grew 18% year-over-year in FY 2025 to $96.5 million, including a 22% rise in BioStorage/BioServices revenue to $18.4 million. Commercial cell and gene therapy (CGT) revenue increased 29% year-over-year to $33.4 million in FY 2025. Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025. Full-year 2026 revenue guidance is set at $190 million to $194 million, representing 8%-10% growth year-over-year. Consolidated gross margin improved to 47.1% for FY 2025, up from 44.4% in FY 2024. Adjusted EBITDA from continuing operations improved by $12 million year-over-year to a negative $5.8 million for FY 2025. Net income for FY 2025 was $78.3 million, primarily driven by the divestiture of the CRYOPDP business. Held $411.2 million in cash, cash equivalents, and short-term investments as of December 31, 2025. Completed the divestiture of the CRYOPDP business to DHL Group on June 11, 2025, which included a substantial capital infusion and contributed $112.3 million net of taxes to income from discontinued operations. Launched a Global Supply Chain Center in Paris, France, and is targeting an opening for a fourth Global Supply Chain Center in Santa Ana, California in late 2026. MVE Biological Solutions introduced integrated Condition Monitoring Solutions for dry vapor shippers and launched the Fusion 800 Series, a self-sustaining cryogenic freezer. Cryoport Systems achieved certification under ISO 21973:2020 for transportation of cells for therapeutic use.